logo

CSTL

Castle Biosciences·NASDAQ
--
--(--)
--
--(--)
4.73 / 10
Netural

Castle Biosciences' fundamentals are mixed yet leaning average: Profit-MV and Cash-MV show strength, but Net profit / Total profit (%) and PB-ROE are flagged as weaker. The Asset-MV score of -0.5007 places it in group 2 with a 15.13% monthly return historical win rate, suggesting moderate upside. Revenue-MV is in group 3 with a 20.82% return, offering some growth promise. However, the low Net profit / Total profit (%) score of 81.4403 in group 1 and a negative Inventory turnover ratio (-0.0316) imply inefficiencies in profitability and inventory management that investors should monitor.

Fundamental(4.73)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.17
Score3/3
Weight42.87%
1M Return20.82%
Inventory turnover ratio
Value6.28
Score2/3
Weight-3.16%
1M Return-2.63%
Gross profit margin (%)
Value79.51
Score2/3
Weight2.06%
1M Return1.47%
Profit-MV
Value0.46
Score2/3
Weight12.46%
1M Return7.79%
PB-ROE
Value0.12
Score0/3
Weight5.69%
1M Return3.56%
Current assets turnover ratio
Value0.72
Score1/3
Weight-0.63%
1M Return-0.48%
Fixed assets turnover ratio
Value3.78
Score2/3
Weight0.16%
1M Return0.12%
Asset-MV
Value-0.50
Score2/3
Weight28.43%
1M Return15.13%
Cash-MV
Value-0.02
Score2/3
Weight12.48%
1M Return7.73%
Net profit / Total profit (%)
Value81.44
Score0/3
Weight-0.37%
1M Return-0.30%
Is CSTL fundamentally strong?
  • CSTL scores 4.73/10 on fundamentals and holds a Fair valuation at present. Backed by its -4.73% ROE, -3.56% net margin, -100.99 P/E ratio, 2.05 P/B ratio, and -286.36% earnings growth, these metrics solidify its Netural investment rating.